Jupiter Neurosciences, Inc. Common Stock Cash Flow Conversion Efficiency
Jupiter Neurosciences, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Jupiter Neurosciences, Inc. Common Stock (JUNS) has a cash flow conversion efficiency ratio of 6.271x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.29 Million) by net assets ($-365.97K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Jupiter Neurosciences, Inc. Common Stock (2019–2025)
Cash flow conversion efficiency of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2025. This chart illustrates how Jupiter Neurosciences, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View JUNS stock price and chart for real-time trading data and today's change.
Jupiter Neurosciences, Inc. Common Stock Cash Flow Conversion Ratio Explained
Jupiter Neurosciences, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Jupiter Neurosciences, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jupiter Neurosciences, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see market cap of Jupiter Neurosciences, Inc. Common Stock for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rubico Inc. Common Stock
NASDAQ:RUBI
|
-0.050x |
|
WEBUY GLOBAL LTD. Ordinary Shares
NASDAQ:WBUY
|
-0.215x |
|
Dialight plc
LSE:DIA
|
0.300x |
|
8I Holdings Ltd
AU:8IH
|
-0.057x |
|
Precomp Solutions AB Series B
ST:PCOM-B
|
-0.069x |
|
Silver Wolf Exploration Ltd
V:SWLF
|
-0.069x |
|
Railway Metrics & Dynamics Sweden AB
ST:RMDX
|
0.026x |
|
Simble Solutions Ltd
AU:SIS
|
1.447x |
Annual Cash Flow Conversion Efficiency for Jupiter Neurosciences, Inc. Common Stock (2019–2025)
The table below shows the annual cash flow conversion efficiency of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2025. Review Jupiter Neurosciences, Inc. Common Stock (JUNS) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.83 Million | $-5.41 Million | 2.955x | +415.26% |
| 2024-12-31 | $4.17 Million | $-3.91 Million | -0.937x | -1230.76% |
| 2023-12-31 | $-5.80 Million | $-480.95K | 0.083x | -52.56% |
| 2022-12-31 | $-7.14 Million | $-1.25 Million | 0.175x | -47.85% |
| 2021-12-31 | $-5.18 Million | $-1.74 Million | 0.335x | +388.09% |
| 2020-12-31 | $-3.71 Million | $-254.78K | 0.069x | +140.91% |
| 2019-12-31 | $-5.02 Million | $-142.95K | 0.028x | -- |
About Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinic… Read more